| Ouverture: | - |
| Variation: | - |
| Volume: | - |
| + Bas: | - |
| + Haut: | - |
| Ecart + Bas / + Haut: | - |
| Type: | Actions |
| Ticker: | APNI |
| ISIN: |
Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
- 19
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market. Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a corporate update.
Company management will also present at the following upcoming investor events and conferences:
-
Bernstein CD28 Day
Presentation: Monday, August 9, 12:15 p.m. ET (9:15 a.m. PT)
Following the presentation, the presented materials from the Bernstein CD28 Day will be available under “Events & Presentations” portion of the Investors section of the company website.
-
2021 Wedbush PacGrow Healthcare Virtual Conference
For Your IOnly - Progress, Challenges in Immuno-Oncology Panel: Wednesday, August 11, 12:35 p.m. ET (9:35 a.m. PT)
Second Quarter 2021 Financial Results Conference Call and Webcast Details
To access the live call by phone, dial (800) 816-3005 (domestic) or (857) 770-0069 (international) and reference conference ID: 8145346. A live webcast of the presentation will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
Source: Alpine Immune Sciences Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005449/en/
